VVUS Related Momentum Movers
-
VIVUS (VVUS) Surges Higher on Aetna Bulletin (ARNA)
-
Arena (ARNA) Runs Higher as VIVUS (VVUS) Seeks Broader Obesity Pill Distribution
-
VIVUS (VVUS) Announces U.S. Market Availability of Qsymia
-
VIVUS (VVUS), Arena (ARNA) Tick Higher on Positive Orexigen (OREX) News
-
Arena (ARNA), Orexigen (OREX) Lift With VIVUS (VVUS)
-
UPDATE: VIVUS (VVUS) Pops Higher Early on Volume; Insider Boosts Stake 12.5%
-
VIVUS (VVUS) Volatile as Qsymia Posted in FDA Orange Book
-
Arena (ARNA) Higher as VIVUS (VVUS) Downgrade is Company-Specific, Not Industry Issue
-
VIVUS (VVUS) Peers Pressured as Analyst Takes Cautious Stance on Obesity Drug (ARNA) (OREX)
-
Arena Pharmaceuticals (ARNA) Jumps on Takeover Speculation
-
VIVUS (VVUS) Slumps to Multi-Month Low, Nears $20 Support Level
-
Arena (ARNA) Looks to Break Losing Streak Following Qsymia Approval (VVUS) (OREX)
-
Biggest Gainers in FY12 To-Date Getting Smacked This Week (ARNA) (VVUS) (LCC)
-
VIVUS (VVUS) Sinks Further on Qsymia Patent Worries
-
VIVUS (VVUS) Weighed-Down by Negative Report
-
Is the Fun Over for Orexigen (OREX)? (VVUS) (ARNA)
-
Orexigen (OREX) Higher Early Following VIVUS (VVUS) Qsymia Approval; Arena (ARNA) Lower
-
VIVUS (VVUS) Resumes Trading +17%
-
Vivus (VVUS) will resume trading at 7:15AM after FDA approval
-
Investors Bid up VIVUS (VVUS) as Early Approval Article Makes the Rounds
-
Just Minutes Left to Trade VIVUS (VVUS) Ahead of Expected FDA Approval
-
VIVUS (VVUS) Hit With Massive 'Bear Raid'; Down as Much as 27%, Before Recovering
-
VIVUS (VVUS) Slammed Early
-
VIVUS (VVUS) Gets a Boost from Uber-Bullish Orexigen (OREX) Call
-
Orexigen (OREX) Higher Early Heading into Qnexa's PDUFA Date (VVUS)
-
With Plenty of Good Arguments for Both Bulls and Bears, VIVUS (VVUS) Qnexa Approval at 50/50 - Jefferies
-
Prospects for Arena's (ARNA) Belviq Are WAY Overblown - Cramer
-
Arena Pharma (ARNA) Dips; Enrollment Accelerated for Orexigen's (OREX) Contrave Trial
-
Arena Pharma (ARNA) Volatility Up; Shares Trade Higher into VIVUS (VVUS) PDUFA for Qnexa
-
UPDATE: JPMorgan Upgrades Orexigen Therapeutics (OREX) to Overweight, Best Opportunity in Obesity Space
-
MannKind (MNKD) Shares Up 10%, Orexigen (OREX) Up 27%, VIVUS (VVUS) Up 9%
-
Arena Pharmaceuticals (ARNA) Must Conduct 6 Post-Marketing Studies
-
VIVUS (VVUS), Orexigen (OREX) Surge on Arena Approval
-
Arena (ARNA) Rivals Mixed Ahead of PDUFA; Volatility Elevated (OREX) (VVUS)
-
Arena-Mania (ARNA) Takes Center Stage and Everyone Has an Opinion
-
Arena Pharmaceuticals (ARNA) is Getting Closer and Closer to the Green Light
-
Arena (ARNA) Ramps as PDUFA Delay May Be Avoided
-
Traders Eying Arena (ARNA) Closely ahead of June PDUFA
-
Arena Pharmaceuticals (ARNA) Comes Off Highs, But Boasts $1B Market Cap
-
VIVUS (VVUS), Orexigen (OREX) Shares Plunge Into Close Ahead of Arena's (ARNA) AdCom on Lorcaserin
-
Arena Pharmaceuticals (ARNA) Surges on VIVUS's (VVUS) Day
-
Investors Continue to Take Profits in Arena (ARNA); Shares Down ~13% Over Last Two Sessions
-
UPDATE: VIVUS (VVUS) Shares Spike 9+%, Orexigen (OREX) Shares Move Lower
-
Traders Watching VIVUS (VVUS) and Other Obesity Drug Makers Ahead of Today's CV Panel (OREX) (ARNA)
-
Editorial Suggests Possible Pre-Approval CV Testing For VIVUS' (VVUS) Qnexa, Others - Analyst
-
VIVUS (VVUS) Could Be Bought For Up to $40/Share
-
VIVUS (VVUS) Sees Pressure Following Equity Offering
-
VIVUS (VVUS) Ticks Lower as CEO Speaks on CNBC
-
VIVUS (VVUS) Continues To Fatten Up on Back of Qnexa, Up 127% Since FDA News
-
Investors Continue Plowing into Vivus (VVUS), Shares Up Over 11%
Back to VVUS Stock Lookup
